Do Not Restart Clopidogrel (Plavix)
In this patient with recent acute ischemic stroke treated with thrombolysis who subsequently developed bilateral pulmonary emboli and is now on apixaban anticoagulation, clopidogrel should NOT be restarted due to the unacceptably high risk of major bleeding from combining antiplatelet therapy with therapeutic anticoagulation.
Primary Rationale
The patient requires therapeutic anticoagulation with apixaban for bilateral PE treatment. Adding clopidogrel to this regimen creates a dangerous combination:
FDA labeling explicitly warns that clopidogrel increases bleeding risk when combined with anticoagulants 1. The Plavix label states: "Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents)."
Apixaban monotherapy is sufficient for both PE treatment and stroke prevention. The FDA label confirms apixaban is indicated for PE treatment at 10 mg twice daily for 7 days, then 5 mg twice daily 2. This provides adequate antithrombotic coverage for both conditions.
Why Dual Therapy Is Contraindicated Here
The Bleeding Risk Outweighs Any Theoretical Benefit
The patient has already demonstrated:
- Recent hemorrhagic transformation risk (post-thrombolysis)
- Active thrombotic disease requiring full anticoagulation
- No clear indication for dual antiplatelet + anticoagulation therapy
The 2021 AHA/ASA Secondary Stroke Prevention Guidelines recommend oral anticoagulation (including apixaban) for stroke prevention in atrial fibrillation, but make no recommendation for adding antiplatelet therapy to therapeutic anticoagulation in standard ischemic stroke patients 3.
Clopidogrel's Role Was for Acute Stroke, Not Ongoing Management
The 2018 AHA/ASA Acute Stroke Guidelines support dual antiplatelet therapy (aspirin + clopidogrel) for minor stroke only, initiated within 24 hours and continued for 21 days 4. This patient:
- Received thrombolysis (indicating moderate-to-severe stroke, not minor)
- Is now beyond the acute phase
- Has developed PE requiring anticoagulation, which supersedes antiplatelet indications
The Correct Management Strategy
Continue apixaban monotherapy at the appropriate dose for PE treatment:
- 10 mg twice daily for first 7 days
- Then 5 mg twice daily ongoing 2
Do not add clopidogrel because:
- Therapeutic anticoagulation addresses both PE and stroke prevention
- The bleeding risk from combination therapy is substantial and well-documented
- No guideline supports combining antiplatelet + therapeutic anticoagulation in this scenario
Critical Pitfalls to Avoid
Don't confuse acute stroke antiplatelet protocols with post-PE anticoagulation management. The clopidogrel was likely initiated for acute stroke management before the PE was discovered. Once therapeutic anticoagulation is required, antiplatelet therapy should be discontinued.
Don't assume "more is better" with antithrombotic therapy. Research consistently shows that combining anticoagulation with antiplatelet agents dramatically increases major bleeding without proportional benefit in most scenarios 1, 5.
Monitor for recurrent thrombotic events on apixaban alone. If paradoxical embolism through a cardiac source (like patent foramen ovale) is suspected, echocardiography should be considered 6, 7, but this doesn't change the recommendation against adding clopidogrel.
Duration of Anticoagulation
Continue apixaban for at least 3 months for PE treatment 8. Reassess for extended duration based on:
- Whether PE was provoked (post-stroke immobility) or unprovoked
- Bleeding risk
- Stroke recurrence risk factors
The apixaban simultaneously provides stroke prevention, eliminating any perceived need for clopidogrel.